Karyopharm Therapeutics (KPTI) PT Lowered to $43 at RBC Capital
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $2.02 +1.51%
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $43.00 (from $45.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
- GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
